# US 2001/0024658 A1 · Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024658 A1
- Document ID: US20010024658A1
- Status: Published application
- Kind: A1
- Application number: 09/751,968
- Filed: 2000-12-29
- Published: 2001-09-27
- Earliest claimed: 1999-08-17
- Assignees: Lipocine Inc.
- Inventors: Feng-Jing Chen; Mahesh V. Patel; David T. Fikstad
- Web page: https://patentgrep.com/patent/US20010024658A1

## CPC

- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 5/38: of the suprarenal hormones
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/06: Antiasthmatics
- A61P 11/14: Antitussive agents
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 33/10: Anthelmintics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A delayed release pharmaceutical dosage form for oral administration of a hydrophilic drug, e.g., a polysaccharide drug such as low molecular weight heparin, are provided. The dosage form comprises a composition of: (a) a therapeutically effective amount of low molecular weight heparin; (b) a bile salt or bile acid; (c) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof; and a means for delaying release of the composition from the dosage form following oral administration. Osmotic drug delivery systems for oral administration of a hydrophilic drug are also provided, wherein an osmotically activated device houses the drug, a bile salt or bile acid, and at least one surfactant selected from the group consisting of hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. Methods for administering hydrophilic drugs, particularly polysaccharide drugs such as low molecular weight heparin, are also provided.

## Claims

### Claim 1

A delayed release pharmaceutical dosage form for oral administration of low molecular weight heparin comprising a composition of (a) a therapeutically effective amount of low molecular weight heparin, (b) a bile salt or a bile acid, (c) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, and (d) a means for delaying release of the composition from the dosage form following oral administration.

### Claim 2 (depends on 1)

The dosage form of claim 1, comprising a capsule containing the composition.

### Claim 3 (depends on 2)

The dosage form of claim 2, wherein the capsule is a starch capsule, a cellulosic capsule, a hard gelatin capsule or a soft gelatin capsule.

### Claim 4 (depends on 1)

The dosage form of claim 1, comprising a tablet or caplet.

### Claim 5 (depends on 1)

The dosage form of claim 1, comprising a plurality of particles, granules, beads, pellets or mixtures thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The dosage form of any one of claims 1 through 5, wherein the means for delaying release comprises an enteric coating on the dosage form.

### Claim 7 (depends on 1)

The dosage form of claim 1, wherein the low molecular weight heparin is present as a coating.

### Claim 8 (depends on 1)

The dosage form of claim 1, wherein the bile salt or bile acid is present as a coating.

### Claim 9 (depends on 8)

The dosage form of claim 8, wherein the means for delaying release comprises an enteric coating on the low molecular weight heparin coating.

### Claim 10 (depends on 8)

The dosage form of claim 8, wherein the means for delaying release comprises an enteric coating on the bile salt or bile acid coating.

### Claim 11 (depends on 2)

The dosage form of claim 2, wherein the composition is comprised of particles, granules, beads, pellets, or mixtures thereof.

### Claim 12 (depends on 11)

The dosage form of claim 11, wherein the means for delaying release comprises an enteric coating on the particles, granules, beads, pellets, or mixtures thereof.

### Claim 13 (depends on 11)

The dosage form of claim 11, wherein the particles, granules, beads, pellets, or mixtures thereof are coated with a coating comprised of low molecular weight heparin.

### Claim 14 (depends on 11)

The dosage form of claim 11, wherein the particles, granules, beads, pellets, powder or mixtures thereof are coated with a coating comprised of a bile salt or bile acid.

### Claim 15 (depends on 13)

The dosage form of claim 13, wherein the means for delaying release comprises an enteric coating on the low molecular weight heparin coating.

### Claim 16 (depends on 14)

The dosage form of claim 14, wherein the means for delaying release comprises an enteric coating on the bile salt or bile acid coating.

### Claim 17 (depends on 1)

The dosage form of claim 1, further including at least one protective coating.

### Claim 18 (depends on 1)

The dosage form of claim 1, wherein the bile salt or bile acid in the coating is in a solubilized, crystalline, amorphous, milled, nanosized, or micronized form.

### Claim 19 (depends on 8, 10, 14, 16)

The dosage form of any one of claims 8, 10, 14 and 16, wherein the bile salt or bile acid in the coating is in a solubilized, crystalline, amorphous, milled, nanosized, or micronized form.

### Claim 20 (depends on 1)

The dosage form of claim 1, wherein the at least one surfactant is a hydrophilic surfactant.

### Claim 21 (depends on 20)

The dosage form of claim 20, wherein the hydrophilic surfactant is an ionic surfactant.

### Claim 22 (depends on 20)

The dosage form of claim 20, wherein the hydrophilic surfactant is a non-ionic surfactant having an HLB value of or greater than about 10.

### Claim 23 (depends on 1)

The dosage form of claim 1, wherein the at least one surfactant is a lipophilic surfactant.

### Claim 24 (depends on 23)

The dosage form of claim 23, wherein the lipophilic surfactant is a non-ionic surfactant having an HLB value of or less than about 10.

### Claim 25 (depends on 23)

The dosage form of claim 23, wherein the lipophilic surfactant is an unionized ionizable surfactant.

### Claim 26 (depends on 1)

The dosage form of claim 1, wherein the at least one surfactant comprises a mixture of a hydrophilic surfactant and a lipophilic surfactant.

### Claim 27 (depends on 26)

The dosage form of claim 26, wherein the hydrophilic surfactant is a non-ionic surfactant having an HLB value of or greater than about 10 and the lipophilic surfactant is a non-ionic surfactant having an HLB value of or less than about 10.

### Claim 28 (depends on 1)

The dosage form of claim 1, wherein the low molecular weight heparin has a molecular weight in the range of approximately 1000 to 10,000 D.

### Claim 29 (depends on 1)

The dosage form of claim 1, wherein the bile salt or bile acid is selected from cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, deoxycholic acid, taurocholic acid, taurodeoxycholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycoursodeoxycholic acid, glycodeoxycholic acid, lithocholic acid, salts of any of the foregoing, and combinations thereof.

### Claim 30 (depends on 29)

The dosage form of claim 29, wherein the bile salt or bile acid is ursodeoxycholic acid or a salt thereof.

### Claim 31 (depends on 29)

The dosage form of claim 29, wherein the bile salt or bile acid is chenodeoxycholic acid or a salt thereof.

### Claim 32 (depends on 1)

The dosage form of claim 1, wherein the bile salt or bile acid and the at least one surfactant are selected such that upon mixing the composition with an aqueous medium at 100× dilution, an optically clear aqueous dispersion is formed having an absorbance of less than about 0.3 at 400 nm.

### Claim 33

A delayed release dosage form for oral administration, comprised of a composition of low molecular weight heparin, a bile salt or acid, and at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, the composition coated with an enteric coating of a bioerodible, gradually hydrolyzable and/or gradually water-soluble coating.

### Claim 34 (depends on 33)

The dosage form of claim 33, wherein the enteric coating is comprised of a cellulosic polymer.

### Claim 35 (depends on 34)

The dosage form of claim 34, wherein the cellulosic polymer is selected from hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose succinate, carboxymethylcellulose sodium, and mixtures thereof.

### Claim 36 (depends on 33)

The dosage form of claim 33, wherein the enteric coating is comprised of an acrylic acid polymer.

### Claim 37 (depends on 36)

The dosage form of claim 36, wherein the acrylic acid polymer is a copolymer of acrylic acid, methacrylic acid, methyl acrylate, ammonio methylacrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate.

### Claim 38 (depends on 33)

The dosage form of claim 33, wherein the enteric coating is comprised of a vinyl polymer selected from polyvinyl pyrrolidone, polyvinyl acetate, polyvinylacetate phthalate, vinylacetate crotonic acid copolymer, and ethylene-vinyl acetate copolymers.

### Claim 39

A pharmaceutical composition comprised of a therapeutically effective amount of low molecular weight heparin, a bile salt or bile acid, at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, and a solubilizer.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the solubilizer is selected from alcohols, polyols, ethers, amides, esters, and mixtures thereof.

### Claim 41 (depends on 40)

The composition of claim 40, wherein the solubilizer is selected from water, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol, glycofurol, diethylene glycol monoethyl ether, propylene glycol, sorbitol, glycerol, ethanol, dimethyl isosorbide, and mixtures thereof.

### Claim 42 (depends on 39)

The composition of claim 39, wherein the low molecular weight heparin is suspended in the composition.

### Claim 43 (depends on 39)

The composition of claim 39, wherein the bile salt or bile acid is at least partially solubilized in the composition.

### Claim 44 (depends on 39)

The composition of claim 39, wherein the bile salt or bile acid is at least partially suspended in the composition in a crystalline, amorphous, nanosized, micronized, or milled form.

### Claim 45 (depends on 39)

The composition of claim 39, wherein the bile salt or bile acid is selected from cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, deoxycholic acid, taurocholic acid, taurodeoxycholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycoursodeoxycholic acid, glycodeoxycholic acid, lithocholic acid, salts of any of the foregoing, and combinations thereof.

### Claim 46 (depends on 45)

The composition of claim 45, wherein the bile salt or bile acid is ursodeoxycholic acid or a salt thereof.

### Claim 47 (depends on 45)

The composition of claim 45, wherein the bile salt or bile acid is chenodeoxycholic acid or a salt thereof.

### Claim 48 (depends on 39)

The composition of claim 39, wherein the composition is substantially free of glycerol triesters of C6 to about C25 fatty acids and propylene glycol diesters of C6 to about C25 fatty acids.

### Claim 49 (depends on 39)

The composition of claim 39, wherein the composition is substantially water-free.

### Claim 50 (depends on 48)

The composition of claim 48, wherein the composition is substantially water-free.

### Claim 51 (depends on 39)

The composition of claim 39, wherein the bile salt or bile acid and the at least one surfactant are selected such that upon mixing with an aqueous medium at 100× dilution, an optically clear aqueous dispersion is formed having an absorbance of less than about 0.3 at 400 nm.

### Claim 52

A drug delivery system for oral administration of a polysaccharide drug, comprising: a first dosage form containing a therapeutically effective amount of the polysaccharide drug; and a second dosage form containing a bile salt or bile acid, in combination with at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, wherein at least one of the dosage forms is a delayed release dosage form.

### Claim 53 (depends on 52)

The drug delivery system of claim 52, wherein the second dosage form and optionally the first dosage form are coated with an enteric coating.

### Claim 54 (depends on 52)

The drug delivery system of claim 52, wherein the polysaccharide drug is selected from glucosamine, glycosaminoglycans, dextran, xylan, pentasaccharide, polygalacturonic acid, polymannuronic acid, chitin, pharmaceutically acceptable salts, esters or other derivatives thereof, and combinations of any of the foregoing.

### Claim 55 (depends on 54)

The drug delivery system of claim 54, wherein the polysaccharide drug is a glycosaminoglycan.

### Claim 56 (depends on 55)

The drug delivery system of claim 55, wherein the glycosaminoglycan is selected from heparin, heparan, chondroitin, dermatan, hyaluronic acid and pharmaceutically acceptable salts thereof.

### Claim 57 (depends on 55)

The drug delivery system of claim 55, wherein the glycosaminoglycan is selected from heparin, low molecular weight heparin, heparin sodium, heparan sulfate, and pharmaceutically acceptable salts of any of the foregoing formed with metallic cations or organic bases.

### Claim 58 (depends on 57)

The drug delivery system of claim 57, wherein the polysaccharide drug is low molecular weight heparin.

### Claim 59 (depends on 57)

The drug delivery system of claim 57, wherein the polysaccharide drug is heparin sodium.

### Claim 60 (depends on 57)

The drug delivery system of claim 57, wherein the polysaccharide drug is heparan.

### Claim 61 (depends on 57)

The drug delivery system of claim 57, wherein the polysaccharide drug is heparan sulfate.

### Claim 62

A method for administering low molecular weight heparin to a patient, comprising orally administering to the patient a delayed release pharmaceutical dosage form comprising (a) a therapeutically effective amount of low molecular weight heparin; (b) a bile salt or bile acid; (c) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof.

### Claim 63

A method for administering a polysaccharide drug to a patient, comprising orally administering to the patient: a first dosage form containing a therapeutically effective amount of the polysaccharide drug; and a second dosage form containing a bile salt or bile acid, in combination with at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, wherein at least one of the dosage forms is a delayed release dosage form.

### Claim 64 (depends on 63)

The method of claim 63, wherein the two dosage forms are administered simultaneously.

### Claim 65 (depends on 63)

The method of claim 63, wherein the first dosage form is administered before the second dosage form is administered.

### Claim 66 (depends on 65)

The method of claim 65, wherein the first dosage form is administered after the second dosage form is administered.

### Claim 67

A pharmaceutical dosage form for oral administration, comprising:
an osmotically activated device housing a therapeutically effective amount of a hydrophilic drug, a bile salt or bile acid, and at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof.

### Claim 68

A delayed release pharmaceutical dosage form for oral administration of a polysaccharide drug, comprising a composition of: (a) a therapeutically effective amount of a polysaccharide drug; (b) a bile salt or bile acid; (c) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof; and (d) a means for delaying release of the composition of the dosage form following oral administration.

### Claim 69 (depends on 68)

The dosage form of claim 68, wherein the polysaccharide drug is selected from glucosamine, glycosaminoglycans, dextran, xylan, pentasaccharide, polygalacturonic acid, polymannuronic acid, chitin, pharmaceutically acceptable salts, esters or other derivatives thereof, and combinations of any of the foregoing.

### Claim 70 (depends on 69)

The dosage form of claim 69, wherein the polysaccharide drug is a glycosaminoglycan.

### Claim 71 (depends on 70)

The dosage form of claim 70, wherein the glycosaminoglycan is selected from heparin, heparan, chondroitin, dermatan, hyaluronic acid and pharmaceutically acceptable salts thereof.

### Claim 72 (depends on 70)

The dosage form of claim 70, wherein the glycosaminoglycan is selected from heparin, low molecular weight heparin, heparin sodium, heparan sulfate, and pharmaceutically acceptable salts of any of the foregoing formed with metallic cations or organic bases.

### Claim 73 (depends on 72)

The dosage form of claim 72, wherein the polysaccharide drug is low molecular weight heparin.

### Claim 74 (depends on 72)

The dosage form of claim 72, wherein the polysaccharide drug is heparin sodium.

### Claim 75 (depends on 72)

The dosage form of claim 72, wherein the polysaccharide drug is heparan.

### Claim 76 (depends on 72)

The dosage form of claim 72, wherein the polysaccharide drug is heparan sulfate.

### Claim 77

A delayed release pharmaceutical dosage form comprising: (a) a therapeutically effective amount of low molecular weight heparin, and (b) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, wherein the dosage form is coated with (c) a coating comprising of a bile salt or bile acid.

### Claim 78

A delayed release pharmaceutical dosage form comprising: (a) a bile salt or acid, and (b) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof, wherein the dosage form is coated with (c) a coating comprised of low molecular weight heparin.

### Claim 79 (depends on 1)

The dosage form of claim 1, wherein the low molecular weight heparin in the composition is solubilized or suspended in a crystalline, amorphous, milled, nanosized, or micronized form.

### Claim 80 (depends on 7, 9, 13, 15)

The dosage form of any one of claims 7, 9, 13 and 15, wherein the low molecular weight heparin in the coating is in a solubilized, crystalline, amorphous, milled, nanosized, or micronized form.
